全国性基于人群的大肠埃希菌血流感染研究:发病率、抗菌药物耐药性与病死率
该研究基于以色列所有医院强制上报的血流感染监测数据与国家死亡登记,纳入2018年1月1日至2019年12月31日所有18岁及以上大肠埃希菌血流感染病例,共11 113例(10 218例患者),年发病率92.5/10万,医院发病较社区发病耐药率更高、病死率更高,耐多药菌株病死率高于非耐多药菌株。
要点
- 大肠埃希菌血流感染年发病率92.5/10万,85%(9012/10 583)为社区发病。
- 医院发病较社区发病耐多药比例更高:65%(1021/1571)vs 45%(4049/9012),p<0.001。
- 医院发病较社区发病病死率更高:14天23% vs 12%,30天31% vs 16%,1年55% vs 34%,p均<0.001。
核心结论
- 大肠埃希菌血流感染疾病负担高,耐多药分离株占很大比例,且与发病率和病死率升高相关。
研究设计与样本
- 基于以色列所有医院向卫生部提交的强制性血流感染监测报告及国家死亡登记进行的全国性基于人群的研究,纳入2018年1月1日至2019年12月31日所有18岁及以上患者的大肠埃希菌血流感染。
主要发现
- 共发生11 113例大肠埃希菌血流感染,涉及10 218例患者;85%(9012/10 583)为社区发病。
- 中位年龄76岁(IQR 65-85),57%(6304/11 113)的病例为女性;年发病率为92.5/10万。
- 医院发病较社区发病耐多药比例更高:65%(1021/1571)vs 45%(4049/9012),p<0.001。
- 医院发病较社区发病病死率:14天23%(276/1214)vs 12%(926/7620),30天31%(378/1214)vs 16%(1244/7620),1年55%(418/766)vs 34%(1645/4903),p均<0.001。
- 耐多药组较非耐多药组1年病死率更高:47%(1258/2707)vs 28%(928/3281),p<0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Escherichia coli is the leading cause of bloodstream infection (BSI). The incidence of E. coli BSI caused by antibiotic-resistant strains is increasing. We aimed to describe the nationwide incidence and resistance profile of E. coli BSI in Israel and its impact on mortality, to compare E. coli BSI mortality with all-cause mortality, and community-onset with hospital-onset E. coli BSIs. METHODS: We used mandatory BSI surveillance reports submitted by all Israeli hospitals to the Ministry of Health and the national death registry. All E. coli BSIs from 1 January 2018 to 31 December 31 2019 in patients aged 18 and over were included. RESULTS: A total of 11 113 E. coli BSIs occurred in 10 218 patients; 85% (9012/10 583) were community onset. Median age was 76 (IQR 65-85), and 57% (6304/11 113) of cases occurred in women. The annual incidence was 92.5 per 100 000 population. Antibiotic resistance was frequent and significantly more common in hospital-onset than in community-onset BSI; 65% (1021/1571) vs. 45% (4049/9012) were multidrug-resistant (MDR) (p < 0.001). The case fatality rate (CFR) was higher following hospital-onset BSI than community-onset: 23% (276/1214) vs. 12% (926/7620) at 14 days, 31% (378/1214) vs. 16% (1244/7620) at 30 days, and 55% (418/766) vs. 34% (1645/4903) at 1 year (p < 0.001 for all comparisons). The 1-year CFR was 47% (1258/2707) for MDR vs. 28% (928/3281) for non-MDR (p < 0.001). The annual mortality rate was 31.0 per 100 000 population, comprising 4.2% (31.0/734.8) of all causes of deaths. DISCUSSION: E. coli BSI carries a high burden, with a large proportion of MDR isolates, which are associated with increased incidence and CFR.
引用
- Feldman SF, Temkin E, Wullfhart L, et al. A nationwide population-based study of Escherichia coli bloodstream infections: incidence, antimicrobial resistance and mortality. Clin Microbiol Infect. 2021. PMID: 34922002. doi:10.1016/j.cmi.2021.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。